MCID: INS002
MIFTS: 52

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
MeSH 43 D002278
NCIt 49 C2917
SNOMED-CT 67 68956006
ICD10 32 D09.9
UMLS 71 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and breast carcinoma in situ. An important gene associated with in Situ Carcinoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Pravastatin and BCG vaccine have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lung, and related phenotypes are cellular and cardiovascular system

Wikipedia : 74 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the in Situ Carcinoma family:

Pre-Malignant Neoplasm Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 674)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 34.2 TP53 PGR ESR1 ERBB2
2 breast carcinoma in situ 32.6 TP53 PGR MIR423 MIR342 MIR335 MIR193A
3 vulvar intraepithelial neoplasia 32.6 TP53 CDH1
4 gynecomastia 31.3 PGR ESR1 ERBB2
5 tubular adenocarcinoma 31.2 PGR ESR1 ERBB2 CDH1
6 intraductal papilloma 31.2 PGR KRT5 ESR1 ERBB2
7 sebaceous adenocarcinoma 31.1 TP53 KRT5 ERBB2
8 mammographic density 31.0 PGR ESR1
9 apocrine adenocarcinoma 30.8 PGR KRT5 ESR1 ERBB2
10 intrahepatic cholangiocarcinoma 30.8 TP53 ERBB2 CDH1
11 mammary paget's disease 30.8 PGR ESR1 ERBB2
12 cervical squamous cell carcinoma 30.8 TP53 MIR143 CDH1
13 cystadenocarcinoma 30.8 TP53 PGR ERBB2
14 ductal carcinoma in situ 30.8 TP53 PGR KRT5 ESR1 ERBB2 CDH1
15 female breast cancer 30.7 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
16 papilloma 30.7 TP53 KRT5 ESR1 CDH1
17 endometrial hyperplasia 30.7 TP53 PGR ESR1
18 spindle cell carcinoma 30.7 PGR KRT5 ESR1 CDH1
19 mucinous adenocarcinoma 30.6 TP53 PGR ESR1 ERBB2
20 tetraploidy 30.6 BRCA2 BRCA1
21 carcinosarcoma 30.6 TP53 PGR ERBB2 CDH1
22 microglandular adenosis 30.5 TP53 PGR ESR1 ERBB2 CDH1
23 vulvar disease 30.5 TP53 PGR ERBB2
24 adenosquamous carcinoma 30.5 TP53 PGR KRT5
25 bilateral breast cancer 30.5 PGR ESR1 ERBB2 CDH1 BRCA2 BRCA1
26 vaginal cancer 30.5 TP53 PRDX2 PGR ESR1
27 cervical adenocarcinoma 30.5 TP53 ESR1 ERBB2
28 renal cell carcinoma, nonpapillary 30.5 TP53 MIR423 MIR335 MIR193A MIR143 CDH1
29 oral squamous cell carcinoma 30.5 TP53 MIR342 MIR193A MIR143 CDH1
30 breast squamous cell carcinoma 30.4 TP53 ERBB2
31 breast fibroadenoma 30.4 TP53 PGR ESR1 ERBB2 CT45A10 BRCA1
32 lobular neoplasia 30.4 TP53 PGR KRT5 ESR1 ERBB2 CT45A10
33 hypertrophy of breast 30.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
34 papillary carcinoma 30.4 PGR ESR1 ERBB2 CDH1
35 cribriform carcinoma 30.4 PGR KRT5 ESR1 ERBB2
36 bladder disease 30.4 TP53 MIR423 MIR342 MIR193A MIR143
37 papillary serous adenocarcinoma 30.4 TP53 PGR BRCA2 BRCA1
38 ovarian serous carcinoma 30.3 TP53 MIR143 ERBB2 CDH1
39 laryngeal disease 30.3 TP53 MIR423 MIR143 CDH1
40 serous cystadenocarcinoma 30.2 TP53 PGR ERBB2 BRCA2 BRCA1
41 pleomorphic adenoma carcinoma 30.2 TP53 ERBB2
42 oropharynx cancer 30.2 TP53 PGR KRT5 ERBB2 CDH1
43 breast adenocarcinoma 30.2 TP53 PGR ESR1 ERBB2
44 rare breast tumor 30.2 TP53 ESR1 ERBB2 BRCA2 BRCA1
45 fallopian tube carcinoma 30.2 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
46 sporadic breast cancer 30.2 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
47 endometrial adenocarcinoma 30.1 TP53 PGR MIR193A ESR1 ERBB2 CDH1
48 ovarian cancer 30.1 TP53 PGR MIR335 MIR193A MIR143 ESR1
49 breast cancer 30.1 TP53 PGR NR3C1 MIR342 MIR335 MIR143
50 gallbladder cancer 30.1 TP53 MIR143 ERBB2 CDH1

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.2 BRCA1 BRCA2 CDH1 ERBB2 ESR1 FKBP4
2 cardiovascular system MP:0005385 10.18 AGTR1 BRCA1 CDH1 ERBB2 ESR1 ITGB4
3 homeostasis/metabolism MP:0005376 10.18 AGTR1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
4 digestive/alimentary MP:0005381 10.13 BRCA1 BRCA2 CDH1 ERBB2 ESR1 FKBP4
5 endocrine/exocrine gland MP:0005379 10.1 BRCA1 BRCA2 CDH1 ERBB2 ESR1 FKBP4
6 immune system MP:0005387 10.06 AGTR1 BRCA1 BRCA2 CDH1 ESR1 ITGB4
7 integument MP:0010771 10 BRCA1 BRCA2 CDH1 ERBB2 ESR1 FKBP4
8 mortality/aging MP:0010768 9.77 AGTR1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
9 limbs/digits/tail MP:0005371 9.7 BRCA1 BRCA2 ERBB2 ESR1 KRT5 PGR
10 neoplasm MP:0002006 9.17 BRCA1 BRCA2 CDH1 ERBB2 ESR1 PGR

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
BCG vaccine Investigational Phase 4
3 Hypolipidemic Agents Phase 4
4 Anticholesteremic Agents Phase 4
5 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
6 Lipid Regulating Agents Phase 4
7 Vaccines Phase 4
8 Immunologic Factors Phase 4
9 Anti-Bacterial Agents Phase 4
10 Alkylating Agents Phase 4
11 Mitomycins Phase 4
12 Antibiotics, Antitubercular Phase 4
13 Adjuvants, Immunologic Phase 4
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
17
Bevacizumab Approved, Investigational Phase 3 216974-75-3
18
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
19
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
20
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
21
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
22
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
23
Pembrolizumab Approved Phase 3 1374853-91-4
24
Fluorouracil Approved Phase 3 51-21-8 3385
25
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
26
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
27
leucovorin Approved Phase 3 58-05-9 6006 143
28
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
29
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
30
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
31
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
32
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
33
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
34
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
35
Aluminum sulfate Approved Phase 3 10043-01-3
36
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
37
Daunorubicin Approved Phase 3 20830-81-3 30323
38
Cidofovir Approved Phase 3 113852-37-2 60613
39
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
40
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
41
Valrubicin Approved Phase 3 56124-62-0 41744
42
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
43
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
44
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
45
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
46
Acetylcarnitine Approved, Investigational Phase 3 3040-38-8 7045767
47
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
49
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 581)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
4 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
5 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
6 Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
7 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
8 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
9 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
10 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
11 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
12 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
13 Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks. Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
14 A Randomized Prospective Open Multicentric Phase III Clinical Trial Compared TC, FEC100 Followed by Docetaxel and EC90 Followed by Paclitaxel as Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients Unknown status NCT01314833 Phase 3 Docetaxel Cyclophosphamide;Cyclophosphamide Fluorouracil Epirubicin Docetaxel;Epirubicin Cyclophosphamide Paclitaxel
15 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
16 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
17 SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS Unknown status NCT00629278 Phase 3 aromatase inhibition therapy;cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;paclitaxel;releasing hormone agonist therapy;tamoxifen citrate
18 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
19 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
20 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
21 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
22 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
23 An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
24 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
25 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
26 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
27 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
28 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
29 A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
30 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
31 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
32 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
33 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
34 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
35 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
36 A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer Completed NCT00233402 Phase 3 Hexvix
37 Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group) Completed NCT02295033 Phase 3
38 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
39 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
40 A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
41 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
42 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
43 A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen Completed NCT00003140 Phase 3 letrozole
44 Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy Completed NCT00352404 Phase 3
45 Photodynamic Diagnosis (PDD) in Flexible Cystoscopy - DaBlaCa-11 Completed NCT02660190 Phase 3 hexaminoavolunate
46 A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) Completed NCT03288987 Phase 3 Bevacizumab + FOLFIRI-3
47 A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma Completed NCT00312000 Phase 3 capecitabine-irinotecan;capecitabine+irinotecan (1st line)
48 A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People With Dysplasia of the Bronchial Epithelium Completed NCT00175747 Phase 2, Phase 3 Inhaled Budesonide 800 µg twice daily
49 Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases Completed NCT00119899 Phase 3
50 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

40
Breast, Cervix, Lung, Lymph Node, Skin, Testis, Testes

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 17162)
# Title Authors PMID Year
1
Papillary urothelial carcinoma of the vagina: A case presentation and review of the literature. 61
31890596 2020
2
Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. 61
32012137 2020
3
Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. 61
31562599 2020
4
The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. 61
31559544 2020
5
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. 61
31018242 2020
6
A patient with squamous cell carcinoma in-situ successfully treated with intralesional 5-Fluorouracil and topical trichloroacetic acid. 61
30843746 2020
7
Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. 61
31786415 2020
8
Non-mass versus mass-like ultrasound patterns in ductal carcinoma in situ: is there an association with high-risk histology? 61
31739979 2020
9
Breast magnetic resonance imaging for estimation of the tumour extent in patients with pure ductal carcinoma in situ: Comparison between full diagnostic and abbreviated protocols. 61
31874302 2020
10
Understanding the histogenesis of a HRAS-PIK3R1 co-driven metastatic metaplastic breast carcinoma associated with squamous metaplasia of lactiferous ducts. 61
31867792 2020
11
Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels. 61
31595577 2020
12
Preoperative assessment of breast cancer: Multireader comparison of contrast-enhanced MRI versus the combination of unenhanced MRI and digital breast tomosynthesis. 61
31838292 2020
13
Flat Epithelial Atypia in Breast Core Needle Biopsies With Radiologic-Pathologic Concordance: Is Excision Necessary? 61
31609784 2020
14
Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. 61
31823173 2020
15
Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer. 61
31562602 2020
16
Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough? 61
31760168 2020
17
Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation. 61
32034117 2020
18
PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. 61
32034486 2020
19
Low-Grade Ductal Carcinoma In Situ. 61
31769792 2020
20
A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer. 61
32037199 2020
21
High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. 61
31446852 2020
22
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. 61
31784095 2020
23
Atypical Ductal Hyperplasia and Lobular Neoplasia: Update and Easing of Guidelines. 61
31825261 2020
24
Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. 61
31837535 2020
25
Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. 61
32034829 2020
26
Ductal carcinoma in situ of the breast: immune cell composition according to subtype. 61
31375764 2020
27
Recommendations to improve patient-centred care for ductal carcinoma in situ: Qualitative focus groups with women. 61
31532871 2020
28
Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. 61
31444238 2020
29
Treatments for primary squamous cell carcinoma and squamous cell carcinoma in situ of the skin: A systematic review and network meta-analysis: Summary of an Agency for Healthcare Research and Quality Comparative Effectiveness Review. 61
31233858 2020
30
Multicentre study of prepectoral breast reconstruction using acellular dermal matrix. 61
32011819 2020
31
Squamous Cell Carcinoma in Lichen Planus of the Esophagus. 61
31323214 2020
32
Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. 61
31734230 2020
33
International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. 61
31431385 2020
34
Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? 61
31375867 2020
35
Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. 61
31823362 2020
36
ASO Author Reflections: Is Sentinel Lymph Node Biopsy Necessary in Patients with Ductal Carcinoma In Situ with Microinvasion Diagnosed on Core Biopsy? 61
31916089 2020
37
Metaplastic (adenosquamous) carcinoma in a phyllodes tumor with osseous metaplasia and ductal carcinoma in situ: A diagnostic challenge on core biopsy. 61
31909550 2020
38
Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials. 61
31602455 2020
39
Application of Contrast-Enhanced Ultrasound in the Diagnosis of Ductal Carcinoma In Situ: Analysis of 127 Cases. 61
31206200 2020
40
Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ. 61
31912259 2020
41
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. 61
31925342 2020
42
Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma. 61
32031116 2020
43
Metaplastic Carcinoma of the Breast: Analysis of 38 Cases from a Single Institute. 61
31769499 2020
44
Elemental bioimaging shows mercury and other toxic metals in normal breast tissue and in breast cancers. 61
32004334 2020
45
Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. 61
31974710 2020
46
Identification and transfer of spatial transcriptomics signatures for cancer diagnosis. 61
31931856 2020
47
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion. 61
31962001 2020
48
Predicting Upstaging of DCIS to Invasive Disease: Radiologists's Predictive Performance. 61
32001164 2020
49
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. 61
31928354 2020
50
Blood DNA Methylation and Breast Cancer: A Prospective Case-Cohort Analysis in the Sister Study. 61
30989176 2020

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.61 TP53 ESR1 ERBB2 CDH1 BRCA2 AGTR1
2
Show member pathways
12.33 TP53 ESR1 ERBB2 CDH1 BRCA2 BRCA1
3
Show member pathways
12.17 TP53 PGR ESR1 ERBB2 CDH1 BRCA2
4
Show member pathways
11.98 PGR NR3C1 ESR1 BRCA1
5 11.74 TP53 ESR1 CDH1 BRCA2 BRCA1
6
Show member pathways
11.68 PGR NR3C1 ESR1
7 11.66 TP53 MIR423 MIR342 MIR335 MIR143 ERBB2
8
Show member pathways
11.63 TP53 BRCA2 BRCA1
9 11.55 TP53 ERBB2 BRCA1
10 11.54 TP53 NR3C1 KRT5 FKBP4
11 11.53 TP53 ERBB2 CDH1
12 11.47 TP53 ERBB2 BRCA1
13 11.42 ITGB4 ERBB2 BRCA1
14 11.04 ITGB4 ERBB2 CDH1
15 10.52 NR3C1 FKBP4

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.17 TP53 PPIA NR3C1 FKBP4 ESR1 BRCA2
2 lateral element GO:0000800 8.96 BRCA2 BRCA1

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.78 TP53 PRDX2 ESR1 BRCA1
2 gene silencing by miRNA GO:0035195 9.76 MIR423 MIR342 MIR193A MIR143
3 hemidesmosome assembly GO:0031581 9.43 KRT5 ITGB4
4 double-strand break repair GO:0006302 9.43 TP53 BRCA2 BRCA1
5 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.4 TP53 ESR1
6 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.37 TP53 ESR1
7 angiotensin-activated signaling pathway GO:0038166 9.32 MIR143 AGTR1
8 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 BRCA1
9 chordate embryonic development GO:0043009 8.96 BRCA2 BRCA1
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP53 PGR ESR1 ERBB2 CDH1 BRCA2
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.62 MIR423 MIR342 MIR193A MIR143
3 steroid hormone receptor activity GO:0003707 9.33 PGR NR3C1 ESR1
4 nuclear receptor activity GO:0004879 9.13 PGR NR3C1 ESR1
5 steroid binding GO:0005496 8.8 PGR NR3C1 ESR1

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....